These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8653482)

  • 1. Relational database for drug-use review of Tennessee Medicaid claims.
    Chyka PA; Holimon TD; Tepedino JT; Petersen H
    Am J Health Syst Pharm; 1996 Jan; 53(2):164-6. PubMed ID: 8653482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug utilization review using a Medicaid claims database.
    Sena MM; Pashko S
    Clin Ther; 1993; 15(5):900-4. PubMed ID: 8269457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug utilization review of sedative/hypnotic agents in Texas Medicaid patients. Texas Medicaid Vendor Drug Program Drug Utilization Review Board.
    Seltzer JK; Kurt TL; Knodel LC; Dean B; Burch C
    J Am Pharm Assoc (Wash); 2000; 40(4):495-9. PubMed ID: 10932458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Medication Adherence and Distance to Dispensing Pharmacies and Prescribers Among an Urban Medicaid Population with Diabetes Mellitus.
    Syed ST; Sharp LK; Kim Y; Jentleson A; Lora CM; Touchette DR; Berbaum ML; Suda KJ; Gerber BS
    Pharmacotherapy; 2016 Jun; 36(6):590-7. PubMed ID: 27087250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicaid program; drug use review program and electronic claims management system for outpatient drug claims--HCFA. Final rule.
    Fed Regist; 1994 Sep; 59(184):48811-25. PubMed ID: 10137645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid drug utilization review annual reports for federal fiscal year 1999: looking back to move forward.
    Fulda TR; Collins T; Kuhle J; Devereaux DS; Zuckerman IH
    J Am Pharm Assoc (2003); 2004; 44(1):69-74. PubMed ID: 14965156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' reactions to the Wisconsin Medicaid drug-use review program.
    Brown CM; Lipowski EE
    Am J Hosp Pharm; 1993 Sep; 50(9):1898-902. PubMed ID: 7907839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of inappropriate drug prescribing by computerized, retrospective DUR screening in Korea.
    Yeom JH; Park JS; Oh OH; Shin HT; Oh JM
    Ann Pharmacother; 2005 Nov; 39(11):1918-23. PubMed ID: 16219902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled letter intervention to change prescribing behavior: results of a dual-targeted approach.
    Collins TM; Mott DA; Bigelow WE; Zimmerman DR
    Health Serv Res; 1997 Oct; 32(4):471-89. PubMed ID: 9327814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TennCare--Medicaid managed care in Tennessee in jeopardy.
    Mirvis DM; Bailey JE; Chang CF
    Am J Manag Care; 2002 Jan; 8(1):57-68. PubMed ID: 11814173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacy participation and claim characteristics in the Wisconsin Medicaid Pharmaceutical Care Program from 1996 to 2007.
    Look KA; Mott DA; Leedham RK; Kreling DH; Hermansen-Kobulnicky CJ
    J Manag Care Pharm; 2012 Mar; 18(2):116-28. PubMed ID: 22380471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicians' experiences with Medicaid managed care: the Tennessee American College of physicians survey on TennCare.
    Bailey JE; Bush AJ; Bertram PD; Somes GW
    Tenn Med; 1998 Aug; 91(8):313-6. PubMed ID: 9697403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
    Bian B; Kelton CM; Guo JJ; Wigle PR
    J Manag Care Pharm; 2010; 16(9):671-9. PubMed ID: 21067253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations.
    Shorr RI; Fought RL; Ray WA
    JAMA; 1994 Feb; 271(5):358-62. PubMed ID: 8283585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-OBRA '90 Medicaid survey: how community pharmacy practice is changing.
    Pugh CB
    Am Pharm; 1995 Feb; NS35(2):17-23. PubMed ID: 7900647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating drug prescribing in a large, ambulatory population: application of an embedded expert system.
    Speedie SM; McNally D; Skarupa S; Michocki R; Rudo C; Metge C; Palumbo F; Knapp D
    Proc Annu Symp Comput Appl Med Care; 1992; ():621-5. PubMed ID: 1482946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization.
    Cooke CE; Fatodu H
    J Manag Care Pharm; 2006 Oct; 12(8):649-55. PubMed ID: 17269843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptococcus pneumoniae-related illnesses in young children: secular trends and regional variation.
    Poehling KA; Szilagyi PG; Edwards K; Mitchel E; Barth R; Hughes H; Lafleur B; Schaffer SJ; Schwartz B; Griffin MR
    Pediatr Infect Dis J; 2003 May; 22(5):413-8. PubMed ID: 12792380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.